The results of multivariable survival analysis for the risk of relapse, which defined as worsening of previous manifestations after a period of at least partial remission, in a patient with GPA based on clinical manifestations at the time of diagnosis with adjustment for the use of cyclophosphamide showed that cavity nodules trended to have an increased relapse rate but did not reach statistical significance, while a presence of anti-PR3 antibody, solid pulmonary nodules, ENT and renal involvement were not associated to the relapse rate [ 33 ].
1
—
—